During the past three decades, the risk of dying from breast cancer in the United States has declined by nearly half, thanks to a combination of screening and early therapy as well as more treatments that are effective with fewer side effects, especial...
Using RNA-seq data of the breast-cancer cell lines we generate a gene-expression model that is a robust predictor of KDM5-inh1 sensitivity. In a test set of breast cancers, this model predicts sensitivity to the compound in a large fraction of HER2+ tumors. In conclusion, KDM5 inhibition...
题目为A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response。 本文对乳腺癌细胞系进行了单细胞分析,以研究肿瘤的异质性和药物反应。作者发现生物标志物的表达存在高度的异质性,并提供了一个框架来确定肿瘤在细胞系组成和药物反应方面的异质性。他们还将细胞系中大规模...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal
在HER2 阳性(HER2+)乳腺癌治疗中,新辅助双 HER2 阻断联合化疗虽已成标准方案,但治疗效果差异大。研究人员开展 “Predictive factors for pCR and relapse following neoadjuvant dual HER2‑blockade in HER2+ breast cancer” 研究,发现 HR 表达等与 pCR、复发相关,有助于制定个性化治疗策略。广告...
12. Lin NU, Winer EP, Wheatley D, et al. A phase II study of afatinib (BIBW 2992), an irrev-ersible ErbB family blocker, in patients with HER2-positive metastatic breast cancer prog-ressing after trastuzumab. ...
In addition, WNT5A augmented cell invasiveness of HER2+ breast-cancer cells. To find WNT5A-induced metastatic-related factors, we did a human cytokine array. The levels of GM-CSF and CXCL8 were significantly increased by WNT5A. CXCL8 also accelerated cell invasiveness in HCC1954 breast-cancer...
Two separate doses of single-agent camizestrant monotherapy improved progression-free survival vs standard-of-care fulvestrant in patients with estrogen receptor-positive, HER2-negative advanced breast cancer.
Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, Rodriguez-Pinilla SM, Mackay A, Tamber N, Fenwick K, Jones C, Dowsett M, Ashworth A, Reis-Filho JS: Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest. 2008, 88:...
Although induction of cell death has been shown by PEITC in MCF-7 cells [48], the effect of PEITC on HER2 has not been reported so far. To ascertain the specificity of PEITC for HER2, we tested the effect of PEITC in two prototype and syngeneic breast cancer cell lines MDA-MB-231, ...